SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Respiratory syncytial virus: diagnosis, prevention and management.

Barr, R; Green, CA; Sande, CJ; Drysdale, SB (2019) Respiratory syncytial virus: diagnosis, prevention and management. Ther Adv Infect Dis, 6. p. 2049936119865798. ISSN 2049-9361 https://doi.org/10.1177/2049936119865798
SGUL Authors: Drysdale, Simon Bruce

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (494kB) | Preview

Abstract

Respiratory syncytial virus (RSV) is responsible for a large burden of disease globally and can present as a variety of clinical syndromes in children of all ages. Bronchiolitis in infants under 1 year of age is the most common clinical presentation hospitalizing 24.2 per 1000 infants each year in the United Kingdom. RSV has been shown to account for 22% of all episodes of acute lower respiratory tract infection in children globally. RSV hospitalization, that is, RSV severe disease, has also been associated with subsequent chronic respiratory morbidity. Routine viral testing in all children is not currently recommended by the United Kingdom National Institute for Health and Care Excellence (NICE) or the American Academy of Pediatrics (AAP) guidance and management is largely supportive. There is some evidence for the use of ribavirin in severely immunocompromised children. Emphasis is placed on prevention of RSV infection through infection control measures both in hospital and in the community, and the use of the RSV-specific monoclonal antibody, palivizumab, for certain high-risk groups of infants. New RSV antivirals and vaccines are currently in development. Ongoing work is needed to improve the prevention of RSV infection, not only because of the acute morbidity and mortality, but also to reduce the associated chronic respiratory morbidity after severe infection.

Item Type: Article
Additional Information: Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Keywords: RSV, cohorting, infection control, nosocomial infection, palivizumab, respiratory syncytial virus
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Ther Adv Infect Dis
ISSN: 2049-9361
Language: eng
Dates:
DateEvent
29 July 2019Published Online
3 July 2019Accepted
Publisher License: Creative Commons: Attribution-Noncommercial 4.0
PubMed ID: 31384456
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/111113
Publisher's version: https://doi.org/10.1177/2049936119865798

Actions (login required)

Edit Item Edit Item